Technology is at the heart of our team's passion.
Our first two FDA-cleared products, the T2Candida Panel and T2Dx Instrument, use T2MR technology to accurately detect Candida – a sepsis-causing bloodstream infection – in an average of 4.3 hours with no blood culture. This rapid detection can help physicians to lower Candida’s 40% mortality rate to 11%.1,2 And this is only the beginning. We are developing products for rapid bacteria detection and hemostasis measurements, which could impact over 11 million patients. We’ve also entered into a partnership with Canon U.S. Life Sciences to improve the detecton of Lyme disease-causing pathogens – a debilitating disease where 3.4 million tests are performed on patients annually.
Learn more about our culture of innovation and collaboration.